Literature DB >> 22295377

Parathyroid carcinoma: increasing incidence and changing presentation.

Sebastian Brown1, Christine O'Neill, James Suliburk, Stan Sidhu, Mark Sywak, Anthony Gill, Bruce Robinson, Leigh Delbridge.   

Abstract

BACKGROUND: Parathyroid carcinoma has been regarded as an exceedingly rare disease worldwide, responsible for less than 1% of cases of primary hyperparathyroidism. However, there have been anecdotal reports recently of an increasing number of patients presenting with parathyroid carcinoma. The aim of this study was to examine the changing incidence and presentation of parathyroid cancer within a single centre. PATIENTS AND METHODS: This is a retrospective case series. Data were obtained from the University of Sydney Endocrine Surgical Unit database, as well as a review of hospital records. All pathology was independently reviewed.
RESULTS: Over the 52-year period of the study from 1958 to 2010, there were 21 cases of confirmed parathyroid cancer. Only three cases were reported in the first 30 years of the study with the majority of cases (n = 11) presenting in the last 5 years. Despite the exponential increase in presentations, no significant differences in demographics or mode of presentation were found.
CONCLUSION: Possible reasons for the dramatic increase in parathyroid cancer include increased screening, an increase in referrals for parathyroid surgery overall associated with the availability of minimally invasive techniques, changes in diagnostic techniques with immunohistochemistry for parafibromin and protein gene product 9.5 (PGP9.5) or possibly a true increase in the incidence of the disease.

Entities:  

Mesh:

Year:  2011        PMID: 22295377     DOI: 10.1111/j.1445-2197.2010.05594.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  15 in total

Review 1.  Understanding the genetic basis of parathyroid carcinoma.

Authors:  Anthony J Gill
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

2.  Is central lymph node dissection necessary for parathyroid carcinoma?

Authors:  Kun-Tai Hsu; Rebecca S Sippel; Herbert Chen; David F Schneider
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

3.  Epidemiology and prognosis of parathyroid carcinoma: real-world data using nationwide cohort.

Authors:  Sung Hye Kong; Jung Hee Kim; Man Young Park; Sang Wan Kim; Chan Soo Shin
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-18       Impact factor: 4.553

Review 4.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

5.  Parathyroid Carcinoma-An Experience of the Enigma Over 10 Years.

Authors:  Supreet Singh Nayyar; Shivakumar Thiagarajan; Devendra Chaukar; Sarbani Ghosh Laskar; Asawari Patil; Abhishek Mahajan; Snehal Shah
Journal:  Indian J Endocrinol Metab       Date:  2020-04-30

6.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

7.  Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis.

Authors:  Ya Hu; Quan Liao; Shaobo Cao; Xiang Gao; Yupei Zhao
Journal:  Endocrine       Date:  2016-06-01       Impact factor: 3.633

8.  Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016.

Authors:  B Sun; B Guo; B Wu; J Kang; X Deng; Z Zhang; Y Fan
Journal:  Osteoporos Int       Date:  2017-12-03       Impact factor: 4.507

Review 9.  MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.

Authors:  Jens Bollerslev; Camilla Schalin-Jäntti; Lars Rejnmark; Heide Siggelkow; Hans Morreau; Rajesh Thakker; Antonio Sitges-Serra; Filomena Cetani; Claudio Marcocci
Journal:  Eur J Endocrinol       Date:  2019-06-01       Impact factor: 6.664

10.  Somatostatin receptor expression in parathyroid neoplasms.

Authors:  Sara Storvall; Helena Leijon; Eeva Ryhänen; Johanna Louhimo; Caj Haglund; Camilla Schalin-Jäntti; Johanna Arola
Journal:  Endocr Connect       Date:  2019-08       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.